Greenrise International’s Medical Hashish Subsidiary Proclaims the Introduction of its Dronabinol Product to the German Market

BERLIN and ERFURT, Germany, November 17, 2021 / CNW / – Greenrise Global Brands Inc. (formerly AMP Alternative Medical Products Inc.) (Frankfurt: C4T) (ISIN: CA39540L1085) (CSE: XCX), wholly owned subsidiary, AMP Alternative Medical Products GmbH (“AMP”), a pharmaceutical Supplier of medical cannabis products for German pharmacies, announces the launch of a new medical cannabis product Dronabinol, which will be available in pharmacies from this year January 2022.

Greenrise Global Logo (CNW Group / Greenrise Global Brands Inc.)

Dronabinol is pure tetrahydrocannabinol (THC) and registered as an active pharmaceutical ingredient (API).

AMP’s Dronabinol product is “Made in.” Germany“It is competitively priced and complements AMP’s portfolio of products, supporting any therapy that requires medical cannabis products for the growing range of therapeutic approaches prescribed by a growing number of physicians.

Dronabinol is a well-known medicinal cannabis product in Germany for many years and is often prescribed by doctors for pain management. Compared to the process of making vaporized forms of medical cannabis, many patients find dronabinol prescriptions easier to take. Doctors believe that the concentration of THC from dronabinol is more accurate than that of flowers or extracts, making dosage monitoring easier. Pharmacists use dronabinol to fill out doctor-prescribed drug prescriptions for patients, usually in the form of drops or solutions.

Is dronabinol Germany the most widely prescribed medical cannabis product, accounting for 35% of all medical cannabis prescriptions and sales of 46.5 million euros in 2020 Germany, total medical cannabis sales with reimbursed prescriptions was 165 million euros, representing nearly 90% of the medical cannabis market in 2020.

AMP’s national sales team is currently being trained by medical professionals to understand the benefits of dronabinol for patients by medical professionals and prescription preparation methods for pharmacists.

The story goes on

AMP has selected a German partner as a dronabinol supplier. Doctors and pharmacists can find more information about the product or how to order on the AMP website: https://amp-eu.com/doccheck-login

“We expect strong sales from this new product as Dronabinol is well known to doctors and insurance companies who reimburse Dronabinol prescriptions frequently,” said Dr. Stefan Feuerstein, Managing Director of AMP and President and Director of Greenrise Global. AMP’s Dronabinol product offers the best quality for patients and the best value for money for pharmacists and insurance companies when compared to the limited number of other products currently on the market. “

About Greenrise Global Brands Inc.

Greenrise Global helps people to recognize the positive properties of cannabis. Greenrise Global is a Canadian public company with two German subsidiaries: Greenrise GmbH (“Greenrise Wellbeing”) and AMP Alternative Medical Products GmbH (“AMP”). Greenrise Wellbeing is a CBD wellness company based in Hamburg, with brands such as Herbify and CANAVEX® in the portfolio. AMP is based in Erfurt and supplies medical cannabis products to pharmacies all over the world Germany, including medical cannabis brands from Aphria, Bedrocan, Little Green Pharma and AMP’s branded product line sold through the nationwide sales team. AMP complies with the German Narcotics Act (BtMG) and the regulatory requirements of the Free State of Thuringia and ensures that products are imported and sold from all over the world Germany meet the standard of good manufacturing practice (EU-GMP) of the European Union.

For more information on Greenrise Global, please visit www.greenriseglobal.com

Neither the CSE nor its regulatory service provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this press release.

This press release contains forward-looking statements based on the company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including its business plans and milestones and their timing. Although the company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. As a result, actual results and results could differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to publicly update them to reflect new information or the occurrence of future events or circumstances, except as required by law.

SOURCE Greenrise Global Brands Inc.

Cision

To download multimedia, see the original content at: http://www.newswire.ca/en/releases/archive/November2021/17/c2637.html